Plasma acylcarnitines and risk of cardiovascular disease: Effect of Mediterranean diet interventions
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Plasma acylcarnitines and risk of cardiovascular disease : Effect of Mediterranean diet interventions. / Guasch-Ferré, Marta; Zheng, Yan; Ruiz-Canela, Miguel; Hruby, Adela; Martínez-González, Miguel A.; Clish, Clary B.; Corella, Dolores; Estruch, Ramon; Ros, Emilio; Fitó, Montserrat; Dennis, Courtney; Morales-Gil, Isabel M.; Arós, Fernando; Fiol, Miquel; Lapetra, José; Serra-Majem, Lluís; Hu, Frank B.; Salas-Salvadó, Jordi.
In: American Journal of Clinical Nutrition, Vol. 103, No. 6, 2016, p. 1408-1416.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma acylcarnitines and risk of cardiovascular disease
T2 - Effect of Mediterranean diet interventions
AU - Guasch-Ferré, Marta
AU - Zheng, Yan
AU - Ruiz-Canela, Miguel
AU - Hruby, Adela
AU - Martínez-González, Miguel A.
AU - Clish, Clary B.
AU - Corella, Dolores
AU - Estruch, Ramon
AU - Ros, Emilio
AU - Fitó, Montserrat
AU - Dennis, Courtney
AU - Morales-Gil, Isabel M.
AU - Arós, Fernando
AU - Fiol, Miquel
AU - Lapetra, José
AU - Serra-Majem, Lluís
AU - Hu, Frank B.
AU - Salas-Salvadó, Jordi
N1 - Publisher Copyright: © 2016 American Society for Nutrition.
PY - 2016
Y1 - 2016
N2 - Background: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention. Objectives: We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions. Design: We measured plasma acylcarnitines with the use of high throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevención con Dieta Mediterránea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected sub cohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study. Results: After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcarnitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcarnitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group. Conclusions: Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcarnitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcarnitines and CVD.
AB - Background: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention. Objectives: We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions. Design: We measured plasma acylcarnitines with the use of high throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevención con Dieta Mediterránea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected sub cohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study. Results: After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcarnitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcarnitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group. Conclusions: Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcarnitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcarnitines and CVD.
KW - Acylcarnitines
KW - Cardiovascular disease
KW - Mediterranean diet
KW - Metabolomics
KW - PREDIMED
U2 - 10.3945/ajcn.116.130492
DO - 10.3945/ajcn.116.130492
M3 - Journal article
C2 - 27099249
AN - SCOPUS:84973175012
VL - 103
SP - 1408
EP - 1416
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - 6
ER -
ID: 358501507